Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Abbott
New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management
April 17th, 2009
Data from a new study showed that Abbott's TRILIPIX(R) (fenofibric acid) delayed-release capsules in combination with rosuvastatin calcium met all of the study's primary endpoints. TRILIPIX 135 mg in combination with rosuvastatin calcium 5 mg significantly improved HDL cholesterol and triglycerides compared to rosuvastatin calcium 5 mg alone, and significantly improved LDL cholesterol compared to TRILIPIX 135 mg alone in patients with multiple lipid problems. Results from this new Phase III study were presented today at the American College of Cardiology's 2009 Scientific Sessions in Orlando. TRILIPIX is a prescription medicine that can be used along with diet to lower...
Source: Health Business Week (2009-04-17)
|
